Skip to main
MGX

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc. has demonstrated significant progress in its gene editing capabilities, achieving durable Factor VIII (FVIII) levels at 80% over a 19-month period in non-human primates, indicating the potential effectiveness of its therapies in treating Hemophilia A. The company's proprietary metagenomics-derived genome editing toolbox, which includes advanced systems for both small and large gene edits, positions it favorably in a competitive biotechnology landscape. Furthermore, Metagenomi's commitment to developing its wholly-owned pipeline while also exploring out-licensing opportunities for ex vivo cell therapy enhances its revenue potential and growth prospects in addressing a range of serious genetic disorders.

Bears say

Metagenomi Inc reported a substantial net loss of $19.9 million, equivalent to $0.54 per share, for the second quarter of 2025, indicating financial strain. The company faces significant risks related to potential delays in advancing its pipeline candidates and the possibility of generating unfavorable clinical data, particularly for its critical programs targeting Hemophilia A and TTR. Additionally, concerns regarding long-term dilution risk may further exacerbate investor apprehension regarding the company's financial health and stock performance.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.